Empirical Financial Services LLC d.b.a. Empirical Wealth Management Buys 2,064 Shares of Hologic, Inc. (NASDAQ:HOLX)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 4.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 45,223 shares of the medical equipment provider’s stock after purchasing an additional 2,064 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Hologic were worth $3,231,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in HOLX. Deseret Mutual Benefit Administrators grew its position in shares of Hologic by 42.2% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 155 shares during the last quarter. Arizona State Retirement System increased its position in Hologic by 0.3% during the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock valued at $4,810,000 after purchasing an additional 172 shares during the period. Lincoln National Corp increased its position in Hologic by 4.0% during the 4th quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock valued at $334,000 after purchasing an additional 178 shares during the period. Allworth Financial LP raised its holdings in Hologic by 39.3% in the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 179 shares in the last quarter. Finally, Great Lakes Retirement Inc. lifted its position in shares of Hologic by 1.6% in the 4th quarter. Great Lakes Retirement Inc. now owns 11,859 shares of the medical equipment provider’s stock worth $847,000 after purchasing an additional 186 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of research reports. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Friday. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. UBS Group boosted their target price on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research report on Friday. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $84.56.

Hologic Stock Up 0.2 %

HOLX stock traded up $0.17 during midday trading on Tuesday, hitting $76.10. The company’s stock had a trading volume of 984,581 shares, compared to its average volume of 1,743,900. The company has a market cap of $17.86 billion, a PE ratio of 38.74, a P/E/G ratio of 2.55 and a beta of 1.01. The firm’s 50-day moving average is $76.15 and its 200-day moving average is $73.14. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $86.74. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company posted $1.06 earnings per share. The company’s quarterly revenue was down .8% on a year-over-year basis. On average, equities research analysts forecast that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Charles J. Dockendorff sold 1,465 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by corporate insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.